Brief: Neurobo Pharmaceuticals Announces Positive Top-Line Data From The SAD Part 1 Of Phase 1 Clinical Trial Evaluating DA-1726

MetaVia

30/09/2024 13:39

Sept 30 (Reuters) - Neurobo Pharmaceuticals Inc
 NRBO.O :
    * NEUROBO PHARMACEUTICALS ANNOUNCES POSITIVE TOP-LINE DATA
FROM
THE SAD PART 1 OF ITS PHASE 1 CLINICAL TRIAL EVALUATING DA-1726
FOR THE TREATMENT OF OBESITY
    * NEUROBO PHARMACEUTICALS INC - DATA SHOWS FAVORABLE SAFETY,
TOLERABILITY, AND DOSE-LINEAR PK
    * NEUROBO PHARMACEUTICALS INC - TOP-LINE DATA FROM MAD PART
2
EXPECTED Q1 2025

Source text for Eikon:  urn:newsml:reuters.com:*:nPncd4wsPa
Further company coverage:  NRBO.O 

 ((Reuters.Briefs@thomsonreuters.com;))